Peptide research profile

Semax

Also known as ACTH(4-7)-Pro-Gly-Pro · MEHFPGP

A synthetic ACTH-fragment analogue developed in Russia for neurologic research. Human reports exist, but many are small, open-label, or not independently replicated.

  • Cognitive & neural
Early human evidence3 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 200 mcg daily calculator row is not the route or exposure used in the best-known human Semax reports, which are predominantly intranasal. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset200 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo injectable ceiling established
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Published Semax studies may report micrograms per kilogram, total milligrams, or nasal solution concentration; these measures are not interchangeable.

Schedule literacy

Patterns described in source material

  • Daily in the recorded preset

    The cadence represented by the recorded calculator presets.

  • Intranasal multi-day courses in stroke reports

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

Human studies do not validate a general wellness or injectable protocol.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Ischemic stroke

    Regional clinical studies examine neurologic recovery when added to standard care.

  • 02

    Neurotrophin signaling

    Animal and cell research measures BDNF, TrkB, and related transcription.

  • 03

    Brain-network effects

    Small placebo-controlled imaging work examines resting-state connectivity.

  • 04

    Neuroprotection

    Preclinical models include ischemia, oxidative stress, and dopaminergic injury.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Small stroke clinical reports

    A 1997 study used non-randomized controls and reported faster regression of selected deficits.

  • Human

    Healthy-volunteer imaging

    Small controlled fMRI work found changes in resting-state network signals, not clinical outcomes.

  • Animal

    BDNF-linked mechanism studies

    Rodent studies report changes in neurotrophin expression after Semax.

Recorded protocol library

Amounts recorded for Semax

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Standard Dose Range · lower endpoint

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Recorded reference

    200 mcg

    Sign in for schedule, duration and source context.

  • 03

    Standard Dose Range · upper endpoint

    500 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Synthetic ACTH(4-7) analogue
Sequence
MEHFPGP
Amino acids
7
Approx. MW
813.9 Da
Origin / design
ACTH(4-7) extended with Pro-Gly-Pro

Important limitations

  • The clinical literature is predominantly Russian and often falls short of modern trial-reporting standards.
  • Imaging and biomarker changes do not establish cognitive enhancement or stroke efficacy.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

3 curated references

  1. Effectiveness of Semax in the acute period of hemispheric ischemic strokeZhurnal Nevrologii i Psikhiatrii · 1997 · Human
  2. Semax regulates BDNF and trkB expression in the rat hippocampusBrain Research · 2006 · Animal
  3. Semax effects on the default mode network in healthy participantsNeuroscience and Behavioral Physiology · 2018 · Human

Related profiles